<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01206309</url>
  </required_header>
  <id_info>
    <org_study_id>RDCRN 6501</org_study_id>
    <secondary_id>U54AI083028-02</secondary_id>
    <secondary_id>RDCRN-6501</secondary_id>
    <secondary_id>2342.00</secondary_id>
    <nct_id>NCT01206309</nct_id>
  </id_info>
  <brief_title>Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation</brief_title>
  <official_title>Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to better understand the onset and course of graft
      versus host disease (GVHD) after stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic cell transplantation (HCT) is the only known curative option for
      many hematologic disorders. After transplantation, many patients develop immune mediated
      disorders that may be life-threatening such as graft versus host disease (GVHD). The
      morbidity and mortality associated with HCT-associated immune mediated disorders are major
      barriers to successful use of transplantation to cure rare hematologic malignancies such as
      leukemia, lymphoma, multiple myeloma, myelodysplastic/myeloproliferative syndromes amongst
      other diseases.

      With this study, the investigators will investigate the biologic basis for immune mediated
      disorders after allogeneic HCT, focusing on those developing cutaneous sclerosis,
      bronchiolitis obliterans syndrome, late acute GVHD and chronic GVHD. The study will enroll
      1118 (1018 adults and 100 children) allogeneic HCT patients over a three year period.
      Subjects will be followed for two years and monitored closely for development of immune
      mediated disorders.  This study will have 5 study visits at day 1, 100, 180, 365, and 730.
      During these visits, a physical assessment, medication review, blood and urine collection
      will occur.

      If a subject develops an immune mediated disordered, they will be monitored at 3 months, 6
      months, 1 year and then annually from the date of diagnosis. During these study visits, a
      physical assessment, IMD status, and medication review as well as blood and urine collection
      will occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Cohort, Time Perspective:  Prospective</study_design>
  <primary_outcome>
    <measure>The prevalence of immune mediated disorders</measure>
    <time_frame>Diagnosis of IMD and at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The prevalence of:
Persistent, recurrent or late onset acute GVHD
Cutaneous Sclerosis
Bronchiolitis Obliterans Syndrome
Chronic GVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Banked blood and urine samples</measure>
    <time_frame>At 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Summarized as the percentage of compliance for each center and for the study as a whole</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1118</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Cutaneous Sclerosis</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Never develop an immune mediated disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Mediated Disorder</arm_group_label>
    <description>Develop an immune mediated disorder</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and urine specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are preparing for or have recently received an allogeneic hematopoietic cell
        transplant
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned or completed first allogeneic stem cell transplant (any conditioning regimen,
             graft source, donor type and GVHD prophylaxis regimen)

          -  Signed, informed consent and, if applicable, child assent

        Exclusion Criteria:

          -  Inability to comply with study procedures

          -  Anticipated survival less than 6 months due to co-morbid disease

          -  Autoimmune disorder or inherited immunodeficiency before HCT

          -  Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of
             HCT or at the time of enrollment (e.g., &gt; 5% blasts for leukemia; poorly responsive
             lymphoma)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Lee, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Chilson</last_name>
    <phone>(206) 667-6069</phone>
    <email>kchilson@fhcrc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Ottani, RN, MSN</last_name>
      <phone>650-721-2372</phone>
      <email>joanne.otani@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sally Arai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Burton, RN, BSN</last_name>
      <phone>813-745-1537</phone>
      <email>michelle.burton@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Pidala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Corey Cutler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Johnson</last_name>
      <phone>612-626-9712</phone>
      <email>joh03025@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Mukta Arora, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Westervelt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Piggee, MPH</last_name>
      <phone>615-875-6120</phone>
      <email>jessica.l.piggee@Vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Madan Jagasia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Hall</last_name>
      <phone>206-667-7010</phone>
      <email>amhall@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie Lee, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeanne Palmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.</citation>
    <PMID>16338616</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 29, 2011</lastchanged_date>
  <firstreceived_date>September 20, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Stephanie Lee</name_title>
    <organization>FHCRC</organization>
  </responsible_party>
  <keyword>Graft vs Host Disease</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Peripheral Blood Stem Cell Transplantation</keyword>
  <keyword>Umbilical Cord Blood Stem Cell Transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
</clinical_study>
